The Pros and Cons of a Single ‘Euro—Price’ For Drugs

@article{Towse1998ThePA,
  title={The Pros and Cons of a Single ‘Euro—Price’ For Drugs},
  author={Dr Adrian Towse},
  journal={PharmacoEconomics},
  year={1998},
  volume={13},
  pages={271-276}
}
Parallel trade in pharmaceuticals has become a major European Union policy issue with several ‘solutions’ being considered by the European Commission, Member State governments and the pharmaceutical industry in the ‘Bangemann Process’. This paper discusses the issues from an economic and public policy perspective — considering the economic cases for differential pricing and for ‘Euro—prices’, concluding that the economic case for parallel trade — to achieve convergence of prices — is not… CONTINUE READING

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Guidelines for the economic evaluation of pharmaceuticals: can the UK learn from Australia and Canada

  • A TowseA.Overview.InTowse, editor
  • London: Office of Health Economics,
  • 1997
Highly Influential
6 Excerpts

Trade and price differentials for pharmaceuticals: policy options

  • P. Danzon
  • London: Office of Health Economics,
  • 1997
Highly Influential
5 Excerpts

Overview

  • A. Towse
  • Health Policy
  • 1997

Round Table ( European Commission , Member States and the pharmaceutical industry ) . Completing the single market

  • P Danzon
  • Trade and price differentials for pharmaceuticals…
  • 1997

Primecrown. Hearing on C-267/95 and C-268/95

  • Merck v
  • Before the European Court of Justice. Brussels,
  • 1996

The effects of price regulation on productivity in pharmaceuticals [working paper

  • P Danzon, A. Percy
  • Philadelphia: The Wharton School, University of…
  • 1996
1 Excerpt

Similar Papers

Loading similar papers…